Treatment
VRT106 clinical trials
We’re tracking 6 recruiting studies that include VRT106, each written for real people, not researchers, below.
Recruiting studies
- NCT07589244RecruitingPhase 2/Phase 3
VRT106 with Camrelizumab and Apatinib for Advanced Liver Cancer
This study tests a combination of three drugs—VRT106 (a new oncolytic virus therapy), camrelizumab (an immune-boosting drug), and apatinib (a targeted cancer drug)—to treat advanced hepatocellular carcinoma (HCC), a type of liver cancer. The goal is to see if this combination works better than standard treatments.
Guangzhou, GuangdongAges 18–75 - NCT06368921RecruitingPhase 1
Study of M1 virus injection for advanced solid tumors
This trial tests a virus called M1 (VRT106) that may be able to infect and destroy cancer cells. It's given by injection directly into a tumor, and is for people whose advanced solid tumors haven't responded to other treatments.
Guangzhou, GuangdongAges 18–75 - NCT06826313RecruitingPhase 1
Virus treatment for advanced solid tumors
This trial tests an intravenous virus treatment (VRT106) for people with advanced solid tumors that have stopped responding to standard therapies. The goal is to see if the virus can target and help control the cancer.
Guangzhou, GuangdongAges 18–75 - NCT06758544RecruitingPhase 1/Phase 2
VRT106 plus chemo for resectable pancreatic cancer
This trial tests a new drug called VRT106 combined with chemotherapy for people with pancreatic cancer that can be surgically removed. The goal is to see if the combination works better than standard treatment alone.
Guangzhou, GuangdongAges 18–75 - NCT07093814RecruitingPhase 1/Phase 2
Testing VRT106 injection for recurrent glioblastoma
This trial tests a new injection called VRT106 for people whose glioblastoma (a brain tumor) has come back or is growing. It uses a virus that may help the immune system attack the tumor. This study is for those who have not had a similar virus or gene therapy before.
Hefei, AnhuiAges 18–70 - NCT07589257RecruitingPhase 2
VRT106 drug combined with radiation for brain stem tumors
This trial tests whether a new drug called VRT106, given alongside radiation therapy, can help treat a serious type of brain tumor called diffuse midline glioma or DIPG. The drug is designed to work with radiation to fight the cancer.
Guangzhou, GuangdongAges 18–75
What VRT106 is being studied for
Conditions with recruiting VRT106 studies.
Common questions
- Are there clinical trials studying VRT106?
- Yes. Clin2 currently lists 6 recruiting studies that include VRT106, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a VRT106 trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is VRT106 an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether VRT106 or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.